Floatz logo

Toremifene

Bone Fracture

GTxSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Bone Fracture cohort.

Asset / SponsorPhaseRating
RISEDRONIC ACID
Boston VA Research Institute, Inc.
Phase 4BB
Calcium
Boston VA Research Institute, Inc.
Phase 4BB
Vitamin D
Boston VA Research Institute, Inc.
Phase 4BB
Sufentanyl
West Virginia University
Phase 4BB
Zoledronate
GlaxoSmithKline
Phase 3B
Denosumab
GlaxoSmithKline
Phase 3B
Viosterol
Brigham and Women's Hospital
UnknownD
Dalteparin
M.D. Anderson Cancer Center
N/ANR

Same molecule, other indications

Toremifene is also rated in:

prostate intraepithelial neoplasiaDormant
BB
Indicative · Phase 3
68 / 100
View asset →
breast carcinoma in situDormant
BB
Indicative · Phase 4
65 / 100
View asset →
invasive breast carcinomaDormant
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →